EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Therapeutic potential of inhibitors of gelatinases MMP ‐2 and MMP ‐9 for the treatment of breast cancer

Alireza Shoari, Mathew A Coban, Evette S Radisky iD

The FEBS Journal · 2026-07 · 293 (13) · 4014-4042

DOI: 10.1111/febs.70343 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 28.11.2025. Verfasst von Alireza Shoari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Matrix Metalloproteinase 9, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinase 2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health (NIH, USA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Matrix metalloproteinases (MMPs) are secreted and cell membrane‐associated enzymes that remodel the extracellular matrix (ECM) and cleave extracellular proteins to promote tumor invasion, angiogenesis, immune evasion, and many other aspects of cancer progression. Among this family, the gelatinases MMP‐2 and MMP‐9, specialized for cleaving collagen IV, are tightly linked to metastatic progression in breast cancer and adverse clinical outcomes. Here, we summarize gelatinase biochemistry and regulation, including zymogen activation, TIMP control, cell‐surface trafficking and tethering, and receptor‐mediated clearance, and explain how crosstalk between ECM and proteases amplifies invasion and metastatic seeding. We then review therapeutic strategies in two parts: direct inhibition and indirect pathway modulation. Direct approaches emphasize selective small molecules (thiirane mechanism‐based inhibitors, allosteric blockers of pro‐MMP‐9 activation) and protein biologics (monoclonal antibodies, nanobodies, engineered TIMPs). Indirect strategies target upstream signals that drive MMP‐2/‐9, including MAPK/AP‐1, PI3K/Akt/mTOR, NF‐κB, EGFR/JAK/STAT, and nuclear receptor and Nrf2/HO‐1 programs, with agents that curb invasion, angiogenesis, and metastasis in breast cancer models. Together, these advances define a maturing toolkit for precise gelatinase control and support prospective evaluation in rational combinations to restrain metastatic progression in high‐risk breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMatrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMatrix Metalloproteinase 2HumansFemaleAnimalsSignal Transduction

Stichwörter der Autor:innen

breast cancergelatinase inhibitorsmatrix metalloproteinasestumor microenvironmenttumor progression

Substanzen

Matrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsMatrix Metalloproteinase 2

Autor:innen und Institutionen

  • Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

ORCID-Profile: Evette S Radisky

Förderung

  • NCI NIH HHS
  • National Institutes of Health (NIH, USA)

Zitieren

APA

Shoari, A., Coban, M. A., & Radisky, E. S. (2026). Therapeutic potential of inhibitors of gelatinases MMP ‐2 and MMP ‐9 for the treatment of breast cancer. The FEBS Journal, 293(13), 4014-4042. https://doi.org/10.1111/febs.70343

Vancouver

Shoari A, Coban MA, Radisky ES. Therapeutic potential of inhibitors of gelatinases MMP ‐2 and MMP ‐9 for the treatment of breast cancer. The FEBS Journal. 2026;293(13):4014-4042. doi:10.1111/febs.70343

BibTeX
@article{Shoari2026,
  author = {Shoari, Alireza and Coban, Mathew A and Radisky, Evette S},
  title = {Therapeutic potential of inhibitors of gelatinases MMP ‐2 and MMP ‐9 for the treatment of breast cancer},
  journal = {The FEBS Journal},
  year = {2026},
  volume = {293},
  number = {13},
  pages = {4014--4042},
  doi = {10.1111/febs.70343}
}
Kostenlos starten →